Pharmaceutical composition for treating hepatitis B and preparation method thereof

Abstract

The invention discloses a pharmaceutical composition for treating hepatitis B and a preparation method thereof. The pharmaceutical composition is prepared by the following components: ganoderma lucidum polysaccharide, radix tetrastigme, disporopsis fuscopicta, radix bupleuri and the like. The preparation method comprises the following steps: weighing the raw materials according to the formula ratio; grinding the above raw materials into coarse powder except for ganoderma lucidum polysaccharide; decocting with water twice, wherein, the first decocting lasts 3h, and the second decocting lasts 2h, filtering, concentrating the filtrate into thick paste; drying, pulverizing; sieving with a 100 meshes sieve; adding ganoderma lucidum polysaccharide; evenly mixing, moistening, softening, and taking out agglomerated product to obtain medicinal granules. The compound preparation prepared by the method of the invention adopts oral dosage form, has convenient use and good mouth feel, is easy to accept by the patients, and has strong function of inhibiting and removing hepatitis B virus, and the negative conversion ratio of HBsAg can reach over 58% after the patient takes the pharmaceutical composition for 6 months; the compound preparation has low treatment cost and can save over 68% of cost compared with the conventional treatment.

Description

technical field [0001] The invention relates to the field of medicines, in particular to a medicine composition for treating hepatitis B with traditional Chinese medicine as the main component and a preparation method thereof. Background technique [0002] Hepatitis B is a disease with global distribution and great social harm. According to an incomplete survey by the World Health Organization, more than 1 million people die of hepatitis every year in the world. my country is now a high-incidence area of ​​hepatitis, and the infection rate of hepatitis B virus in the national population is 42%-80%, and about 1 / 4 of the carriers of hepatitis B virus eventually develop into liver cirrhosis and primary liver cancer, accounting for about 50% of the world's hepatitis B virus. more than half of the patients. Hepatitis B is a multi-organ involvement, low function performance, complex pathogenesis, long course, easy to relapse, difficult to cure disease. Modern medicine still has ...

Images